Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
PAH survival unaffected by rheumatoid arthritis origin

PAH survival unaffected by rheumatoid arthritis origin

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Mechanistic subtypes of IPAH revealed

Mechanistic subtypes of IPAH revealed

Concentric remodelling preserves right ventricular function in PAH

Concentric remodelling preserves right ventricular function in PAH

Peripheral muscles weakened in PAH patients

Peripheral muscles weakened in PAH patients

CT measures can refine PAH prognosis

CT measures can refine PAH prognosis

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

PAH markers identified among Chinese systemic sclerosis patients

PAH markers identified among Chinese systemic sclerosis patients

Cardiac monitoring foretells clinical deterioration in PAH

Cardiac monitoring foretells clinical deterioration in PAH

Noninvasive PAH diagnosis on the horizon

Noninvasive PAH diagnosis on the horizon

Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

HRQoL goals may improve outcome in PAH

HRQoL goals may improve outcome in PAH

Noninvasive measure has prognostic value in PAH

Noninvasive measure has prognostic value in PAH

Targeted treatments may improve idiopathic PAH survival

Targeted treatments may improve idiopathic PAH survival

Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Cardiac arrhythmias pose risk in pulmonary hypertension patients

Cardiac arrhythmias pose risk in pulmonary hypertension patients

New potential therapeutic targets for treatment of pulmonary arterial hypertension

New potential therapeutic targets for treatment of pulmonary arterial hypertension

New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension